active: true
branding:
    icon_url: https://api.polygon.io/v1/reference/company-branding/bWVzb2JsYXN0LmNvbQ/images/2025-04-04_icon.jpeg
    logo_url: https://api.polygon.io/v1/reference/company-branding/bWVzb2JsYXN0LmNvbQ/images/2025-04-04_logo.jpeg
cik: 0001345099
composite_figi: BBG000QD6LZ1
currency_name: usd
description: Mesoblast Ltd is a biotechnology company. It uses its proprietary technology
    platform to develop and commercialize allogeneic cellular medicines to treat complex
    diseases resistant to conventional standards of care and where inflammation plays
    a central role. The company's product candidates include; Ryoncil (remestemcel-L)
    for the treatment of steroid refractory acute graft versus host disease as well
    as for the treatment of moderate to severe acute respiratory distress syndrome;
    Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L
    for chronic low back pain. The company is managed as one operating segment, being
    the development of cell technology platform for commercialization.
homepage_url: https://www.mesoblast.com
list_date: '2009-01-05'
locale: us
market: stocks
market_cap: 1943445481.32
name: Mesoblast Limited American Depositary Shares
primary_exchange: XNAS
round_lot: 100
share_class_figi: BBG001SMNB80
share_class_shares_outstanding: 127996719
ticker: MESO
ticker_root: MESO
total_employees: 73
type: ADRC
weighted_shares_outstanding: 127942428
